Get the Stockscreener App
0.51
2.31%
0.0115
After Hours:
.53
0.02
+3.92%
Oragenics Inc stock is traded at $0.51, with a volume of 8,293.
It is up +2.31% in the last 24 hours and down -7.27% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.4985
Open:
$0.4992
24h Volume:
8,293
Relative Volume:
0.25
Market Cap:
$2.30M
Revenue:
$7,500
Net Income/Loss:
$-9.83M
P/E Ratio:
-0.0834
EPS:
-6.1164
Net Cash Flow:
$-9.33M
1W Performance:
-2.71%
1M Performance:
-7.27%
6M Performance:
-40.78%
1Y Performance:
-51.89%
1-Day Range:
$0.4992
$0.52
1-Week Range:
$0.4901
$0.5329
52-Week Range:
$0.4801
$1.45
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.51 | 2.44M | 7,500 | -9.83M | -9.33M | -6.1164 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics Faces Potential NYSE American Delisting on Equity Shortfall - Minichart
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress - TipRanks
Oragenics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Oragenics (NYSE: OGEN) faces NYSE listing warning as equity falls short - Stock Titan
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - Yahoo Finance
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics: Q2 Earnings Snapshot - AOL.com
Oragenics (OGEN) flags going concern risk with $4.7M loss and $3.9M cash - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Oragenics (OGEN) Gains 2% as Micro-Cap Biotech Holds Key Support at $0.47Technical Analysis - vinanet.vn
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Interim Report - vinanet.vn
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesEBITDA Analysis - vinanet.vn
Oragenics Inc. Revenue Breakdown – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Cash Flow - TradingKey
OGEN|Oragenics Inc|Price:0.507|Chg%:-0.004 - TradingKey
TradingKey - TradingKey
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueRevenue Guidance Update - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesPost-Earnings Drift - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesCost Structure Review - vinanet.vn
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineBPI Bear Correction - dars.gov.et
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineGuidance vs Actual - vinanet.vn
Oragenics Incto Receive Exclusive License - Moomoo
Form 4 Oragenics Inc For: 7 July By Investing.com - Investing.com Nigeria
Oragenics (OGEN) CFO receives 55,900 stock options at $0.59 exercise price - Stock Titan
ORAGENICS (OGEN) CFO reports initial holdings, including 10,000-share stock option grant - Stock Titan
Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002 - citybuzz -
Oragenics Achieves Full Activation of Australian Phase IIa Trial NetworkAll Three Sites Now Enrolling - The Manila Times
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
Oragenics Appoints New Chief Financial Officer and Leader - TipRanks
Oragenics, Inc. Announces Appointment of John Spencer to Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
OGEN Q2 2023 Earnings: EPS Beat Driven by Cost Control Amid Ongoing Clinical DevelopmentEarnings Forecast Report - dars.gov.et
Price to earnings forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Narrowed Loss Surpasses Estimates, Stock Declines Amid No RevenueEarnings Quality Analysis - DonanımHaber
OGEN Q2 2023 Earnings: Narrower-Than-Expected Loss as Shares Drift LowerAnalyst Consensus Shift - po-news-eg.net
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Significant EPS Beat Amidst No Revenue ReportedTrough Earnings Signal - dars.gov.et
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics (OGEN) Sees Minor Pullback as Biotech Stock Holds Above Key SupportMA Cross Alert - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat as Operating Loss NarrowsPretax Income Report - po-news-eg.net
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
Oragenics Inc. (OGEN) Holds Near $0.59 Support Amid Low Volatility – Key Levels in FocusEquity Put Call - dars.gov.et
OGENOragenics Inc Short Interest - Finviz
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor Sentiment Despite Stock DeclineGuidance Revision Trend - po-news-eg.net
Oragenics Inc (OGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):